Some studies have shown that S1P had a cardioprotective effect and could protect against ischemic myocardium, which may depend on the activation of RhoA and its downstream protein kinase D. At present, drugs for CHD and ischemia-reperfusion targeting S1P receptor are being developed [39–41]. This evidence concerns the gene PRKD1 and coronary artery disorder.